Marshall Wace North America’s Arcturus Therapeutics ARCT Stock Holding History

Marshall Wace North America’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$1.91M	Buy	+39,972	New	+$1.79M	0.01%	739

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $38.6B AUM 35.31% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $153M AUM

Marshall Wace North America's ARCT Position: Q3 2021 in Review

Marshall Wace North America opened a new position in Arcturus Therapeutics (ARCT) in Q3 2021: 39,972 shares worth $1.91M. The stake represents 0.01% of the portfolio and ranks #739 among its holdings.

156 funds tracked by Wall St. Rank hold ARCT as of Q3 2021.

Marshall Wace North America held 39,972 shares of Arcturus Therapeutics worth $1.91M as of Q3 2021.
Arcturus Therapeutics was a new Marshall Wace North America position in Q3 2021.
Arcturus Therapeutics made up 0.01% of Marshall Wace North America's portfolio in Q3 2021, its #739 holding.
156 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.